Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Relugolix Shows Comparable Castration Resistance–Free Survival to Leuprolide Acetate in Prostate Cancer

September 29th 2020

Relugolix was not found to achieve statistical superiority with regard to castration resistance–free survival versus leuprolide acetate in patients with metastatic prostate cancer through 48 weeks.

Germline BRCA2 Status, Other Aberrations Independently Linked With Cause-Specific Survival in Prostate Cancer

September 29th 2020

Patients with prostate cancer who harbor germline BRCA2 mutations were found to have significantly higher rates of somatic BRCA loss, somatic RB1 loss, and MYC amplification compared with non-carriers—factors that were independently associated with poorer survival outcomes.

PARP Inhibitors Underscore the Need for Routine Germline Testing in Prostate Cancer

September 29th 2020

Ajjai Shivaram Alva, MBBS, discusses the role of PARP inhibitors in prostate cancer, the importance of germline testing, and the need for personalized medicine.

Darolutamide/ADT Data Published in NEJM Underscore Survival Benefit for Nonmetastatic CRPC

September 29th 2020

Final data from the pivotal phase 3 ARAMIS trial with darolutamide and androgen deprivation therapy showed that the combination continued to demonstrate a statistically significant improvement in overall survival versus ADT alone in patients with nonmetastatic, castration-resistant prostate cancer.

Dr. Petrylak on Pivotal PARP Inhibitor Trials in mCRPC With DNA Repair Mutations

September 28th 2020

Daniel P. Petrylak, MD, discusses the pivotal trials that have led to the regulatory approvals of the PARP inhibitors olaparib and rucaparib in patients with metastatic castration-resistant prostate cancer and DNA repair mutations.

Dr. Azad on the Post-Hoc Analysis of the ARCHES Study in mHSPC

September 28th 2020

Arun Azad, PhD, discusses the results of the post-hoc analyses of the phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer.

Dr. Petrylak on the Role of PSA Screening in Prostate Cancer

September 28th 2020

Daniel P. Petrylak, MD, discusses the role of prostate-specific antigen screening in prostate cancer.

FDA Approval Sought for Prostate Cancer Imaging Product TLX591-CDx

September 27th 2020

A new drug application has been submitted to the FDA for TLX591-CDx, a radiopharmaceutical product that targets prostate-specific membrane antigen, for the imaging of prostate cancer through the use of positron emission tomography.

Dr. Hussain on the Importance of Genomic Profiling in mCRPC

September 25th 2020

Maha Hussain, MD, FACP, FASCO, discusses the importance of genomic profiling in metastatic castration-resistant prostate cancer.

Dr. Nguyen on Standard and Investigational Treatment Options in High-Risk Prostate Cancer

September 25th 2020

Paul L. Nguyen, MD, discusses standard and investigational treatment options in high-risk prostate cancer.

Dr. Azad on Unmet Needs in Metastatic Hormone-Sensitive Prostate Cancer

September 25th 2020

Arun Azad, PhD, discusses unmet needs for men with metastatic hormone-sensitive prostate cancer.

Apalutamide Maintains Health-Related QoL Among Men With Nonmetastatic CRPC

September 25th 2020

With more than 4 years of follow-up, the health-related quality of life of men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy was shown to be maintained with the addition of apalutamide.

Dr. Hussain on the Clinical Impact of the PROfound Trial in mCRPC

September 24th 2020

Maha Hussain, MD, FACP, FASCO, discusses the clinical impact of the phase 3 PROfound trial in metastatic castration-resistant prostate cancer.

Dr. Nguyen on the Optimal Duration of ADT in High-Risk Prostate Cancer

September 23rd 2020

Paul L. Nguyen, MD, discusses the optimal duration of androgen deprivation therapy in patients with high-risk prostate cancer.

Dr. Shore on the Objective of the HERO Trial in Advanced Prostate Cancer

September 23rd 2020

Neal D. Shore, MD, FACS, discusses the objective of the phase 3 HERO trial in advanced prostate cancer.

Dr. Choudhury on Treatment Goals in Nonmetastatic CRPC

September 23rd 2020

Atish D. Choudhury, MD, PhD, discusses the goal of treating patients with nonmetastatic castration-resistant prostate cancer.

VERU-111 Demonstrates Preliminary Viability in Pretreated mCRPC

September 23rd 2020

Continuous administration of the novel tubulin inhibitor VERU-111 proved to be safe and demonstrated antitumor activity, evidenced by prostate-specific antigen reductions, objective tumor responses, and durable activity, in men with previously treated metastatic castration-resistant prostate cancer.

Dr. Choudhury on the Safety Profiles of Antiandrogens in Nonmetastatic CRPC

September 22nd 2020

Atish D. Choudhury, MD, PhD, compares the safety profiles of antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Dr. Hussain on the Safety Profile of Olaparib in the PROfound Trial in mCRPC

September 22nd 2020

Maha Hussain, MD, FACP, FASCO, discusses the safety profile of olaparib as observed in the phase 3 PROfound trial in men with metastatic castration-resistant prostate cancer.

Dr. Trinh on Re-Establishing Standard Surgical Procedures in Prostate Cancer

September 22nd 2020

Quoc-Dien Trinh, MD, discusses the challenges of re-establishing standard surgical procedures in patients with prostate cancer following the initial wave of the coronavirus disease 2019 pandemic.